natgillin/translations-raw huggingface dataset:
A pharmaceutical composition comprising the compound of formula I as claimed in claim 5 together with customary pharmaceutical excipients and/or vehicles. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj formule I prema zahtjevu 5, zajedno s uobičajenim farmaceutskim pomoćnim sredstvima i/ili nosačima.
A pharmaceutical composition comprising one or more compound(s) of formula I or a salt, a N-oxide or a salt of a N-oxide of this (these) compound(s) as claimed in any one of claims 6 or 7 together with customary pharmaceutical excipients and/or vehicles. 
Farmaceutski sastav, naznačen time, da obuhvaća jedan ili više spojeva formule I ili njegovu sol, njegov N-oksid ili sol od N-oksida toga ili tih spojeva prema bilo kojem od zahtjeva 6 ili 7, zajedno s uobičajenim farmaceutskim pomoćnim sredstvima i/ili nosačima.
Use of the compound of formula I or a salt of this compound as claimed in claim 4 for the production of pharmaceutical compositions for the treatment of bronchial asthma, COPD, psoriasis or atopic eczema. 
Uporaba spoja formule I ili njegove soli prema zahtjevu 4, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje bronhijalne astme, COPD-a, psorijaze ili atopičnog ekcema.
Use of the compound of formula I or a salt of this compound as claimed in claim 4 for the production of pharmaceutical compositions for the treatment of diabetes mellitus. 
Uporaba spoja formule I ili njegove soli prema zahtjevu 4, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje mellitus dijabetesa.
Use of the compound of formula I as claimed in claim 5 for the production of pharmaceutical compositions for the treatment of bronchial asthma, COPD, psoriasis or atopic eczema. 
Uporaba spoja formule I prema zahtjevu 5, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje bronhijalne astme, COPD-a, psorijaze ili atopičnog ekcema.
Use of the compound of formula I as claimed in claim 5 for the production of pharmaceutical compositions for the treatment of diabetes mellitus. 
Uporaba spoja formule I prema zahtjevu 5, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje mellitus dijabetesa.
Use of a compound of formula I or a salt, a N-oxide or a salt of a N-oxide of this compound as claimed in any one of claims 6 or 7 for the production of pharmaceutical compositions for the treatment of bronchial asthma, COPD, psoriasis, atopic eczema or diabetes mellitus. 
Uporaba spoja formule I ili njegove soli, njegovog N-oksida ili soli od N-oksida toga spoja prema bilo kojem od zahtjeva 6 ili 7, naznačena time, da je za proizvodnju farmaceutskih sastava za liječenje bronhijalne astme, COPD-a, psorijaze, atopičnog ekcema ili mellitus dijabetesa.
The compound of formula I or a salt of this compound as claimed in claim 4 for use in the treatment of bronchial asthma, COPD, psoriasis or atopic eczema. 
Spoj formule I ili njegova sol prema zahtjevu 4, naznačen time, da se upotrebljava za liječenje bronhijalne astme, COPD-a, psorijaze ili atopičnog ekcema.
The compound of formula I as claimed in claim 5 for use in the treatment of bronchial asthma, COPD, psoriasis or atopic eczema. 
Spoj formule I prema zahtjevu 5, naznačen time, da se upotrebljava za liječenje bronhijalne astme, COPD-a, psorijaze ili atopičnog ekcema.
A compound of formula I or a salt, a N-oxide or a salt of a N-oxide of this compound as claimed in any one of claims 6 or 7 for use in the treatment of bronchial asthma, COPD, psoriasis, atopic eczema or diabetes mellitus. 
Spoj formule I ili njegova sol ili njegov N-oksid, ili sol od N-oksida toga spoja prema bilo kojem od zahtjeva 6 ili 7, naznačen time, da se upotrebljava za liječenje bronhijalne astme, COPD-a, psorijaze, atopičnog ekcema ili mellitus dijabetesa.
The pharmaceutical composition of claim 28, further comprising an additional therapeutic agent. 
Farmaceutski sastav prema zahtjevu 28, naznačen time, da nadalje obuhvaća dodatno terapeutsko sredstvo.
The pharmaceutical composition of claim 6, wherein the additional therapeutic agent is selected from an anticancer compound, an analgesic, an antiemetic, an antidepressant, and an anti-inflammatory agent. 
Farmaceutski sastav prema zahtjevu 6, naznačen time, da je dodatno terapeutsko sredstvo odabrano između protutumorskog sredstva, analgetika, antiemetika, antidepresiva i protuuplanog sredstva.
The compound for use in a method of treatment according to claim 15 or the use of claim 16, wherein the cancer to be treated is selected from the group consisting of lung carcinoma, pancreatic carcinoma, bladder carcinoma, colon carcinoma, myeloid disorders, prostate cancer, thyroid cancer, melanoma, adenomas and carcinomas of the ovary, eye, liver, biliary tract, and nervous system. 
Spoj za uporabu u postupku liječenja prema zahtjevu 8 ili uporaba prema zahtjevu 9, naznačen(a) time, da se rak koji treba liječiti, odabire iz skupine koju čine: karcinom pluća, karcinom pankreasa, karcinom mjehura, karcinom debelog crijeva, mijeloidni poremećaji, rak prostate, tiroidni rak, melanom, te adenomi i karcinomi jajnika, oka, jetre, bilijarnog stabla i nervnog sustava.
The compound for use in a method of treatment according to claim 8 or the use of claim 9, further comprising administering to the subject an additional therapeutic agent, optionally wherein the additional therapeutic agent is a different Raf kinase inhibitor or an inhibitor of MEK, mTOR, HSP90, AKT, PI3K, CDK9, PAK, Protein Kinase C, a MAP kinase, a MAPK Kinase, or ERK, and the additional therapeutic agent is administered to the subject concurrently with the compound. 
Spoj za uporabu u postupku liječenja prema zahtjevu 8 ili uporaba prema zahtjevu 9, naznačen(a) time, da nadalje obuhvaća davanje dodatnog terapeutskog sredstva pojedincu, pri čemu je opcijski dodatno terapeutsko sredstvo neki drugi inhibitor Raf-kinaze ili je inhibitor za sljedeće: MEK, mTOR, HSP90, AKT, PI3K, CDK9, PAK, C-kinaza proteina, MAP-kinaza, MAPK-kinaza ili ERK, te se dodatno terapeutsko sredstvo daje pojedincu istovremeno sa spojem.
The compound for use in a method of treatment of claim 11 or the use of claim 11, wherein: 
Spoj za uporabu u postupku liječenja prema zahtjevu 11 ili uporaba prema zahtjevu 11, naznačen(a) time, da:
the additional therapeutic agent comprises an anticancer drug, a pain medication, an antiemetic, an antidepressant or an anti-inflammatory agent; or 
dodatno terapeutsko sredstvo obuhvaća protutumorski lijek, lijek protiv bolova, antiemetik, antidepresiv ili protuupalno sredstvo; ili
The compound for use in a method of treatment of any one of claims 8-12 or the use of any one of claims 8-12, wherein the compound is for treating a condition mediated by Raf kinase, optionally wherein the Raf kinase is a mutant b-Raf kinase such as b-Raf(V600E). 
Spoj za uporabu u postupku liječenja prema bilo kojem zahtjevu od 8 do 12 ili uporaba prema bilo kojem zahtjevu od 8 do 12, naznačen(a) time, da je to spoj za liječenje stanja posredovanog Raf-kinazom, pri čemu je opcijski Raf-kinaza mutirala od b-Raf-kinaze, kao primjerice b-Raf(V600E).
or a stereoisomer of the compound. 
ili stereoizomer toga spoja.
is an unsubstituted phenyl, or a stereoisomer of the compound. 
je nesupstituirani fenil, ili stereoizomer toga spoja.
Pharmaceutical composition comprising at least one of the compounds of formula 1 or a stereoisomer thereof according to any one of claims 1 to 9 together with at least one pharmaceutically acceptable auxiliary. 
Farmaceutski sastav, naznačen time, da obuhvaća barem jedan od spojeva formule 1 ili njegovih stereoizomera prema bilo kojem od zahtjeva 1 do 9 zajedno s barem jednim farmaceutski prihvatljivim pomoćnim sredstvom.
A solid formulation comprising a homogenous dispersion of pimobendan or a pharmaceutically acceptable salt thereof in citric acid or its anhydride and a flavor acceptable to small animals, wherein the solid formulation is obtainable by a fluid-bed granulation process comprising the steps: 
Kruti pripravak, naznačen time, da obuhvaća homogenu disperziju pimobendana ili njegovu farmaceutski prihvatljivu sol u limunskoj kiselini ili njezinom anhidridu i dodatak za okus prihvatljiv za male životinje, pri čemu se kruti pripravak može dobiti pomoću granulacijskog postupka na fluidiziranom sloju, koji obuhvaća sljedeće korake:
an aqueous solution of pimobendan and a binder is sprayed onto a solid support comprising one or several excipients, flavor and citric acid anhydrous; and 
vodena otopina pimobendana i veziva se raspršuje na kruti nosač koji sadrži jedno ili nekoliko pomoćnih sredstava, dodatak za okus i anhidrid limunske kiseline; i
the mixture of b) is sieved and de-agglomerated; and 
smjesa iz koraka b) se prosijava i deaglomerira; i
a flow regulator is added to the mixture of c); and 
u smjesu iz koraka c) se dodaje regulator protoka; i
a lubricant is added to the mixture of d); and 
u smjesu iz koraka d) se dodaje lubrikant; i
the mixture of e) is blended for uniformity of granules to obtain final granules; and/or 
smjesa iz koraka e) se miješa za postizanje jednolikosti granula za dobivanje konačnih granula; i/ili
the final granules of f) are compressed to tablets. 
gotove granule iz koraka f) se stlačuju u tablete.
The solid formulation according to claim 2 or 3, characterized in that the binder is selected from the group consisting of polyvidone/povidone, methylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxymethylcellulose, starch and gelatine. 
Kruti pripravak prema zahtjevu 1 ili 2, naznačen time, da je vezivo odabrano iz skupine koju čine polividon/povidon, metilceluloza, hidroksipropilmetilceluloza (HPMC), hidroksimetilceluloza, škrob i želatina.
The solid formulation according to claims 4, characterized in that the lactose consists of coarse particles greater than 200 µm in size. 
Kruti pripravak prema zahtjevu 4, naznačen time, da se laktoza sastoji od grubih čestica većih od 200 μm.
The solid formulation according to any one of claims 1 to 12, characterized in that the content of pimobendan in relation to citric acid anhydrous is 1:10 to 1:40, preferably 1:20. 
Kruti pripravak prema bilo kojem od zahtjeva 1 do 11, naznačen time, da je sadržaj pimobendana u odnosu na sadržaj anhidrida limunske kiseline u omjeru 1:10 do 1:40, poželjno 1:20.
an aqueous solution of pimobendan and a binder is sprayed onto a solid support comprising one or several carriers and/or excipients, flavor and citric acid anhydrous; and 
vodena otopina pimobendana i veziva se raspršuje na kruti nosač koji sadrži jedan ili nekoliko nosača, jedno ili nekoliko pomoćnih sredstava, dodatak za okus i anhidrid limunske kiseline; i
an aqueous solution of pimobendan and povidone is sprayed onto a solid support comprising lactose, starch, flavor and citric acid anhydrous; and 
vodena otopina pimobendana i povidona se raspršuje na kruti nosač koji sadrži laktozu, škrob, dodatak za okus i anhidrid limunske kiseline; i
A kit comprising a solid formulation according to any one of claims 1 to 17 and a package leaflet or user instruction including the information that said formulation is to be used for the prevention and/or treatment of congestive heart failure in a mammal, preferably in a dog, cat or rodent, in need of such prevention or treatment. 
Garnitura, naznačena time, da obuhvaća kruti pripravak prema bilo kojem od zahtjeva 1 do 16 i pakirani listić ili uputstvo za korisnika, koji sadrži informaciju da se kruti pripravak treba upotrebljavati za prevenciju i/ili liječenje kongestivnog srčanog zastoja kod sisavca, poželjno kod psa, mačke ili glodavca, kojima treba takva prevencija ili liječenje.
a herbicide B which is selected from the group consisting of dicamba, its salts and its esters; 
herbicid B koji je izabran iz grupe koju čine dikamba, njegove soli i njegovi esteri;
where the herbicidal composition besides herbicide A and herbicide B contains no further herbicide D, which is different from herbicide A and herbicide B. 
pri čemu herbicidna kompozicija pored herbicida A i herbicida B ne sadrži dodatni herbicid D, koji se razlikuje od herbicida A i herbicida B.
The use as claimed in claim 6, where the crop plants are resistant to synthetic auxin herbicides. 
Uporaba prema patentnom zahtjevu 6, naznačena time što su biljne kulture otporne na herbicide sintetičkog auksina.
The conjugate according to claim 1, having a surface electrostatic absolute charge of at least 25 mV under physiological conditions. 
Konjugat u skladu s patentnim zahtjevom 1, koji ima površinski elektrostatski apsolutni naboj od najmanje 25 mV u fiziološkim uvjetima.
A process for the preparation of a conjugate of formula (I) as defined in claim 1, comprising the following steps: 
Postupak za pripremu konjugata formule (I) definiranog u patentnom zahtjevu 1, obuhvaća sljedeće korake:
The composition according to claim 11, to be administered by intravenous, subcutaneous or intramuscular injection. 
Sastav prema patentnom zahtjevu 11, za davanje intravenskom, subkutanom ili intramuskularnom injekcijom.
The conjugate for use according to claim 13, wherein the nanoparticle is a gold nanosphere having a diameter from 4 to 20 nm. 
Konjugat za uporabu u skladu s patentnim zahtjevom 13, pri čemu je nanočestica zlatna nanosfera koja ima promjer od 4 do 20 nm.
optionally converting the thus obtained (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol into an acid addition salt. 
opcionalno pretvaranje tako dobivenog (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenola u kiselo adicijsku sol.
A process according to any one of claims 1 to 3, characterized in that the inert reaction medium in step (a) is selected from the group consisting of diethyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, tert-butyl-methylether, diisopropylether or any mixture thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time da je inertni reakcijski medij u koraku (a) izabran iz skupine koja se sastoji od dietil etera, tetrahidrofurana, 2-metiltetrahidrofurana, terc-butil-metiletera, diizopropiletera ili bilo koje njihove smjese.
A process according to claim 20, characterized in that the catalyst used for hydrogenation is selected from the group consisting of Raney nickel, palladium, palladium on carbon, platinum, platinum on carbon, ruthenium on carbon or rhodium on carbon. 
Postupak prema zahtjevu 7, naznačen time da je katalizator korišten za hidrogenaciju izabran iz skupine koja se sastoji od Raney nikla, paladija, paladija na ugljenu, platine, platine na ugljenu, rutenija na ugljenu ili rodija na ugljenu.
The method according to claims 1 to 5, wherein the TNFa inhibitor is an anti-TNFa antibody. 
Kombinacija za uporabu u skladu s patentnim zahtjevima 1 do 5, naznačena time, da je TNFa inhibitor protu-TNFa protutijelo.
A method for preparing a polymorph form as defined in any one of claims 1 to 2, which comprises treating 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide with methanesulfonic acid at a temperature between 20-80°C. 
Postupak dobivanja polimorfnog oblika u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što se sastoji u obradi 4-(4-metilpiperazin-1-ilmetil)-N-[4-metil-3-(4-piridin-3-iltiazol-2-ilamino)fenil]benzamida metansulfonskom kiselinom, na temperaturi između 20 i 80 °C.
A surfactant product according to claim 1, wherein the surfactant is selected from the group consisting of sodium laureth sulfate, cocamide diethanolamine, lauryl betaine and mixtures thereof. 
Proizvod surfaktanta prema zahtjevu 1, naznačen time da je surfaktant odabran iz skupine koja sadrži natrijev lauret sulfat, kokamid dietanolamin, lauril betain i njihove mješavine.
preparing a mixture comprising a surfactant, sodium carbonate and cream of tartar; 
pripremu smjese koja sadrži surfaktant, natrijev karbonat i vinski kamen;
A cosmetic method comprising contacting moist skin of a user with the surfactant product as defined in claims 1 to 8. 
Kozmetički postupak naznačen time da se sastoji od kontaktiranja vlažne kože korisnika sa proizvodom surfaktanta kako je definirano u zahtjevima od 1 do 8.
hypertension before, during, or after surgery, 
hipertenzija prije, za vrijeme, ili nakon operacije,
instructions for using the pharmaceutical composition of (a) for the treatment of a condition selected from the group consisting of: 
instrukcija za uporabu farmaceutskog pripravka iz (a) za liječenje stanja koje je odabrano iz skupine koju čine:
an ischemic heart condition, preferably stable angina, unstable angina, or vasospastic angina, 
ishemijskog stanja srca, poželjno stabilna angina, nestabilna angina, ili vazospastična angina,
no-reflow phenomenon following reperfusion, a disease associated with decreased skeletal muscle blood flow, preferably Raynaud's phenomenon or intermittent claudication, 
bolest povezana sa smanjenim protokom krvi u skeletnim mišićima, poželjno Raynaudov fenomen ili intermitentna klaudikacija, pri čemu se navedeno liječenje sastoji od davanja spoja navedenom pacijentu.
wherein said treating comprises administering the compound to said patient. The kit of claim 9, wherein when said condition is an ischemic heart condition or cardiac arrhythmia, said administering comprises sublingual, buccal, transdermal, intranasal, or inhalation administration, or when said condition is a hypertensive crisis in an emergency room setting, said administering comprises sublingual, buccal, intranasal, inhalation, or parenteral administration, preferably said parenteral administration is intravenous administration, or when said condition is hypertension before, during, or after surgery, or no-reflow phenomenon following reperfusion, said administering comprises parenteral administration, preferably intravenous administration, or when said condition is a disease associated with decreased skeletal muscle blood flow, said administering comprises sublingual, buccal, transdermal, intranasal, inhalation, or topical administration. 
Komplet prema zahtjevu 9, naznačen time da kada je navedeno stanje ishemijsko stanje srca ili srčana aritmija, navedena primjena je sublingvalna, bukalna, transdermalna, intranazalna, ili inhalacijska primjena, ili kada je navedeno stanje hipertenzivna kriza u sobi za hitne slučajeve, navedena primjena je sublingvalna, bukalna, intranazalna, inhalacijska, ili parenteralna primjena, poželjno navedena parenteralna primjena je intravenozna primjena, ili kada je navedeno stanje hipertenzija prije, za vrijeme, ili nakon operacije, ili fenomen odsutnosti protoka poslije reperfuzije, navedena primjena je parenteralna primjena, poželjno intravenozna primjena, ili kada je navedeno stanje bolest povezana sa smanjenim protokom krvi u skeletnim mišićima, navedena primjena je sublingvalna, bukalna, transdermalna, intranazalna, inhalacijska, ili topikalna primjena.
Apparatus according to claim 1, characterized in that the coded structure (34, 134) has an analogue structure or a digital structure, making it possible to sense these structures by means of the sensor device (4, 4', 4"). 
Naprava prema zahtjevu 1, naznačena time da kodirana struktura (34, 134) ima analognu strukturu ili digitalnu strukturu, tako da je moguće provoditi nadzor navedenih struktura pomoću senzorskog uređaja (4, 4', 4").
Apparatus according to Claim 1 or 2, characterized in that the apparatus can be combined with a lid (2) of the cooking vessel, the adjusting element (3) projecting into the lid space (37) through an opening (38) in the lid. 
Naprava prema zahtjevu 1 ili 2, naznačena time da se naprava može kombinirati sa poklopcem (2) posude za kuhanje, te se element za podešavanje (3) pruža u prostor poklopca (37) kroz otvor (38) na poklopcu.
Apparatus according to Claim 3, characterized in that the opening (38) is of circular configuration and has a diameter in the range from 5 mm to 50 mm. 
Naprava prema zahtjevu 3, naznačena time da je otvor (38) kružnog oblika i ima promjer u rasponu od 5 mm do 50 mm.
Apparatus according to one of the preceding claims, characterized in that the apparatus further comprises an input device (6) these input device (6) being permanently connected to the sensor device (4, 4', 4"). 
Naprava prema jednom od prethodnih zahtjeva, naznačena time da naprava dodatno sadrži ulazni uređaj (6), te je navedeni ulazni uređaj (6) stalno povezan sa senzorskim uređajem (4, 4', 4").
Apparatus according to Claim 5, characterized in that the input device can be connected via the measuring disc (31) and the setting disc (32) such that it can be coupled to the lid handle (2). 
Naprava prema zahtjevu 5, naznačena time da ulazni uređaj može biti spojen preko mjernog diska (31) i diska za podešavanje (32) tako da se može spojiti na dršku poklopca (2).
Apparatus according to one of Claims 5 to 7, characterized in that the input device (6) comprises at least an input key (61) and a display panel (62). 
Naprava prema jednom zahtjevu od 5 do 7, naznačena time da ulazni uređaj (6) sadrži barem tipku za unos (61) i ploču zaslona (62).
Apparatus according to one of Claims 1 to 8, characterized in that the control means comprises a transmitter with the aid of which it is possible to generate a control signal which can be transmitted in a wireless fashion to a receiver of a heating apparatus acting on the cooking vessel. 
Naprava prema jednom zahtjevu od 1 do 8, naznačena time da kontrolna sredstva sadrže odašiljač pomoću kojeg je moguće generirati kontrolni signal koji se na bežični način može prenositi do prijemnika uređaja za zagrijavanje koji djeluje na posudu za kuhanje.
An insect resistant corn plant, or parts thereof, or seed thereof or progeny thereof comprising a DNA molecule encoding Cry2Ab and Cry1A.105 in the genome in the cells of said corn plant, parts, seed or progeny thereof, wherein the DNA molecule comprises the following elements: e35S promoter, wheat CAB untranslated leader, rice actin intron, coding sequence for Cry1A.105, wheat HSP17 3' termination and polyadenylation sequence, FMV promoter, hsp70 intron, rubisco small subunit chloroplast targeting peptide coding sequence, Cry2Ab coding sequence, nos 3' termination and polyadenylation signal sequence, wherein positioned on opposite ends of said DNA molecule are a DNA having the nucleotide sequence of SEQ ID NO:1 and a DNA having the nucleotide sequence of SEQ ID NO:2, and wherein said DNA molecule is present in the corn event MON89034 deposited with American Type Culture Collection (ATCC) with Accession No. 
Biljka kukuruza otporna na insekte, ili dijelovi iste, ili sjeme iste, ili potomstvo iste sadrže DNA molekulu koja kodira Cry2Ab i Cry1A.105 u genom u stanice navedene biljke kukuruza, dijelove, sjeme ili potomstvo iste, pri čemu DNA molekula sadrži slijedeće elemente: e35S promotor, CAB neprevođenu začetnicu pšeničnog gena, aktinski intron iz gena riže, Cry1A.105 kodirajuću sekvencu, HPS17 3’ terminacijsku i poliadenilacijsku sekvencu pšenice, FMV promotor, hsp70 intron, kodirajuću sekvencu za malu podjedinicu kloroplasnog rubisco ciljnog peptida, Cry2Ab kodirajuću sekvencu, nos 3’ terminacijsku i poliadenilacijsku signalnu sekvencu, pri čemu su na suprotne krajeve opisane molekule DNA dodane nukleotidne sekvence SEQ ID NO: 1 i sekvenca SEQ ID NO: 2, i pri čemu je spomenuta DNA molekula prisutna u kukuruzu oznake MON89034 pohranjenog kod American Type Culture Collection (ATCC) s pristupnim brojem PTA-7455.
PTA-7455. The insect resistant corn plant, or parts thereof, or seed thereof or progeny thereof of claim 1, comprising the nucleotide sequence of SEQ ID NO:5. 
Biljka kukuruza otporna na insekte, ili dijelovi iste, ili sjeme iste, ili potomstvo iste prema zahtjevu 1 sadrže nukleotidnu sekvencu SEQ ID NO:5.